Skip to main
  1. Stocks
  2. Atrium Therapeutics Inc
  3. Forecast
RNA

RNA Stock Forecast & Price Target

RNA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atrium Therapeutics is compelling because its lead asset ATR 1072 has already cleared IND, entered Corventis, and could provide the first human evidence of myocardial delivery, PRKAG2 knockdown, and repeat-dose tolerability in 2H27. The company’s investment case is strengthened by a focused, genetically defined PRKAG2 population of at least 1,000-2,000 in the U.S., preclinical data showing about 85% cardiac PRKAG2 mRNA reduction in NHPs and meaningful functional rescue in mice, and a balance sheet of $267.8 million in cash plus ~$46.5 million in estimated net proceeds that extends runway through 2028. Upside is further supported by ATR 1086, which showed 100% survival in a severe PLN mouse model and ~80% cardiac PLN mRNA reduction in NHPs, while collaboration milestones and patent coverage into the mid-2040s add capital efficiency and long-duration strategic value.

Bears say

Atrium Therapeutics is a high-risk early clinical-stage biotech with no product revenue, so its value depends entirely on ATR 1072, ATR 1086 and other pipeline assets progressing through costly development, regulatory review and eventual commercialization. Its outlook is weakened by dependence on Avidity/Novartis-controlled RNA-delivery IP and the possibility of competing cardiovascular products, which clouds freedom to operate and reduces the durability of any competitive moat. Fundamental risk is further elevated by uncertain safety in genetically constrained cardiomyopathy populations, possible dilution if cash needs rise, and reimbursement pressure that could limit adoption even if the programs are approved.

RNA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atrium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

RNA Analyst Forecast & Price Prediction

Get the latest RNA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atrium Therapeutics Inc (RNA) Forecast

Analysts have given RNA a Buy based on their latest research and market trends.

According to 5 analysts, RNA has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atrium Therapeutics Inc (RNA)


RNA Analyst Forecast & Price Prediction

Get the latest RNA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in RNA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RNA stock data and trends